000212490 001__ 212490
000212490 005__ 20240229154912.0
000212490 0247_ $$2doi$$a10.3389/fcell.2022.1080626
000212490 0247_ $$2pmid$$apmid:36684421
000212490 0247_ $$2pmc$$apmc:PMC9852825
000212490 0247_ $$2altmetric$$aaltmetric:140915811
000212490 037__ $$aDKFZ-2023-00191
000212490 041__ $$aEnglish
000212490 082__ $$a570
000212490 1001_ $$0P:(DE-He78)a8b399fa71eacddc353846ca1d9d2127$$aPecori, Riccardo$$b0$$eFirst author$$udkfz
000212490 245__ $$aADAR RNA editing on antisense RNAs results in apparent U-to-C base changes on overlapping sense transcripts.
000212490 260__ $$aLausanne$$bFrontiers Media$$c2023
000212490 3367_ $$2DRIVER$$aarticle
000212490 3367_ $$2DataCite$$aOutput Types/Journal article
000212490 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698997917_23208
000212490 3367_ $$2BibTeX$$aARTICLE
000212490 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212490 3367_ $$00$$2EndNote$$aJournal Article
000212490 500__ $$a#EA:D150#LA:D150# / HI-TRON
000212490 520__ $$aDespite hundreds of RNA modifications described to date, only RNA editing results in a change in the nucleotide sequence of RNA molecules compared to the genome. In mammals, two kinds of RNA editing have been described so far, adenosine to inosine (A-to-I) and cytidine to uridine (C-to-U) editing. Recent improvements in RNA sequencing technologies have led to the discovery of a continuously growing number of editing sites. These methods are powerful but not error-free, making routine validation of newly-described editing sites necessary. During one of these validations on DDX58 mRNA, along with A-to-I RNA editing sites, we encountered putative U-to-C editing. These U-to-C edits were present in several cell lines and appeared regulated in response to specific environmental stimuli. The same findings were also observed for the human long intergenic non-coding RNA p21 (hLincRNA-p21). A more in-depth analysis revealed that putative U-to-C edits result from A-to-I editing on overlapping antisense RNAs that are transcribed from the same loci. Such editing events, occurring on overlapping genes transcribed in opposite directions, have recently been demonstrated to be immunogenic and have been linked with autoimmune and immune-related diseases. Our findings, also confirmed by deep transcriptome data, demonstrate that such loci can be recognized simply through the presence of A-to-I and U-to-C mismatches within the same locus, reflective A-to-I editing both in the sense-oriented transcript and in the cis-natural antisense transcript (cis-NAT), implying that such clusters could be a mark of functionally relevant ADAR1 editing events.
000212490 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000212490 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212490 650_7 $$2Other$$aADAR
000212490 650_7 $$2Other$$aDDX58/RIG-I
000212490 650_7 $$2Other$$aLINC-P21
000212490 650_7 $$2Other$$aMultiEditR
000212490 650_7 $$2Other$$aRNA editing
000212490 650_7 $$2Other$$aU-to-C
000212490 7001_ $$aChillón, Isabel$$b1
000212490 7001_ $$aLo Giudice, Claudio$$b2
000212490 7001_ $$0P:(DE-He78)7c776439971ef21f36ac730cfbff7fff$$aArnold, Annette$$b3$$udkfz
000212490 7001_ $$0P:(DE-He78)06a6077b0cfcb0f4890fb5f2543c43be$$aWüst, Sandra$$b4$$udkfz
000212490 7001_ $$0P:(DE-He78)2fb2bd9048a3777dddc4cb89b115c187$$aBinder, Marco$$b5$$udkfz
000212490 7001_ $$aMarcia, Marco$$b6
000212490 7001_ $$aPicardi, Ernesto$$b7
000212490 7001_ $$0P:(DE-He78)79dbda58d51b613a0a421f579d2dfed3$$aPapavasiliou, Fotini$$b8$$eLast author$$udkfz
000212490 773__ $$0PERI:(DE-600)2737824-X$$a10.3389/fcell.2022.1080626$$gVol. 10, p. 1080626$$p1080626$$tFrontiers in cell and developmental biology$$v10$$x2296-634X$$y2023
000212490 909CO $$ooai:inrepo02.dkfz.de:212490$$pVDB
000212490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8b399fa71eacddc353846ca1d9d2127$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000212490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7c776439971ef21f36ac730cfbff7fff$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000212490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)06a6077b0cfcb0f4890fb5f2543c43be$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000212490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2fb2bd9048a3777dddc4cb89b115c187$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000212490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79dbda58d51b613a0a421f579d2dfed3$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000212490 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000212490 9141_ $$y2023
000212490 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-13T10:29:32Z
000212490 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-13T10:29:32Z
000212490 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-13T10:29:32Z
000212490 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-12
000212490 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000212490 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000212490 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-12
000212490 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-12
000212490 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT CELL DEV BIOL : 2022$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-13T10:29:32Z
000212490 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000212490 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT CELL DEV BIOL : 2022$$d2023-10-26
000212490 9202_ $$0I:(DE-He78)D150-20160331$$kD150$$lD150 Immundiversität$$x0
000212490 9201_ $$0I:(DE-He78)D150-20160331$$kD150$$lD150 Immundiversität$$x0
000212490 9201_ $$0I:(DE-He78)F170-20160331$$kF170$$lF170 Virus-assoziierte Karzinogenese$$x1
000212490 9200_ $$0I:(DE-He78)D150-20160331$$kD150$$lD150 Immundiversität$$x0
000212490 980__ $$ajournal
000212490 980__ $$aVDB
000212490 980__ $$aI:(DE-He78)D150-20160331
000212490 980__ $$aI:(DE-He78)F170-20160331
000212490 980__ $$aUNRESTRICTED